menu
    • menu
    [{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Li.."},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Yale School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceruvia Lifesciences \/ Yale School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Ceruvia Li.."},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceruvia Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Li.."}]

    Find Clinical Drug Pipeline Developments & Deals by Ceruvia Lifesciences

    Menu

    Ceruvia Lifesciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial

                            Details : NYPRG-101, also referred to in the literature as BOL-148 (2-bromo-d-lysergic acid diethylamide), is a non-hallucinogenic analog of LSD, differing by only one atom. It is currently in phase 1 clinical tria...

                            Product Name : BOL-148

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Yale School of Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compu...

                            Details : The primary endpoint of the trial is to determine the reduction in OCD symptoms for up to 12 weeks after a single administration of SYNP-101 (psilocybin).

                            Product Name : SYNP-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Yale School of Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            Ceruvia Lifesciences

                            U.S.A arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Preve...

                            Details : NYPRG-101 (2-bromo-D-lysergic acid diethylamide), referred as BOL-148, is a non-hallucinogenic analog of LSD. Results from IND-enabling pre-clinical toxicology work as well as research conducted with huma...

                            Product Name : NYPRG-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : 2-Bromo-Lysergic Acid Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth